SCHEMBL2759112

SCHEMBL2759112

CC(C)c1ccnc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.42
LOX P28300 1/20 0.42
LOXL3 P58215 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
TRPA1 O75762 2/20 0.38
SMARCA2 P51531 3/20 0.36
SMARCA4 P51532 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.35
PFKFB3 Q16875 1/20 0.35
IDO1 P14902 1/20 0.35
CHRNA7 P36544 1/20 0.35
PTGS1 P23219 1/20 0.34
CACNA1C Q13936 1/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
MAP4K4 O95819 1/20 0.34
PAK4 O96013 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30713880 0.87 RECQL (0.39) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL7993514 0.84 RECQL (0.41) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL24724094 0.83 RECQL (0.44) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL4330263 0.83 RECQL (0.44) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL30003916 0.83 RECQL (0.44) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL24387376 0.83 ADRB2 (0.45) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL2040052 0.83 RECQL (0.44) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL23475190 0.83 RECQL (0.39) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL17000217 0.83 RECQL (0.39) RECQLLOXLOXL3LOXL2TRPA1
SCHEMBL30003331 0.83 RECQL (0.44) RECQLLOXLOXL3LOXL2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112321494-B Method for preparing 2-chloro-4-isopropylpyridine 上海凌凯医药科技有限公司 2022-04-19 CN claimed
CN-112321494-A Method for preparing 2-chloro-4-isopropylpyridine 上海凌凯医药科技有限公司 2021-02-05 CN claimed
US-20250374818-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO LTD (KR) 2025-12-04 US disclosed
US-20250333644-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2025-10-30 US disclosed
EP-3915996-B1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORP (US) 2025-09-10 EP disclosed
US-12279517-B2 Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-04-15 US disclosed
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 EP disclosed
CN-114901660-B Substituted bicyclic compounds useful as T cell activators 百时美施贵宝公司 2024-10-15 CN disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 US disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 US disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 US disclosed
US-20080058331-A1 Inhibitors for GlyT-1 HOFFMANN-LA ROCHE INC. 2008-03-06 US disclosed
US-20070232610-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-10-04 US disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 RECQL 964/4885LOX 4108/4885LOXL3 3800/4885
US-20250374818-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE L1CAM, CHRM1, AP1M1 RECQL 3431/4885LOX 1782/4885LOXL3 932/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 RECQL 964/4885LOX 4108/4885LOXL3 3800/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 RECQL 1132/4885LOX 1399/4885LOXL3 2016/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 RECQL 1366/4885LOX 3071/4885LOXL3 4397/4885
US-20080058331-A1 Inhibitors for GlyT-1 GLRA1, SLC1A2, AGXT RECQL 2312/4885LOX 1154/4885LOXL3 1657/4885
US-20070232610-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 RECQL 1366/4885LOX 3071/4885LOXL3 4397/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK RECQL 1308/4885LOX 4488/4885LOXL3 4451/4885
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 RECQL 3747/4885LOX 4359/4885LOXL3 4361/4885
US-12279517-B2 Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device CYBA, CHRM1, FOXM1 RECQL 3130/4885LOX 607/4885LOXL3 176/4885
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLRMT, POLR2H RECQL 826/4885LOX 3022/4885LOXL3 3568/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 RECQL 4347/4885LOX 69/4885LOXL3 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.